Empiric Treatment for Carbapenem-Resistant Bacterial Infections
For suspected carbapenem-resistant Gram-negative infections, initiate empiric therapy with novel β-lactam/β-lactamase inhibitor combinations (ceftazidime-avibactam or ceftolozane-tazobactam for CRE/CRPA, or sulbactam-durlobactam for CRAB) in patients with septic shock, severe immunocompromise, endovascular infections, or high-risk sources. 1, 2
Risk Stratification Determines Empiric Approach
Your empiric treatment strategy hinges on three factors:
- Infection severity: Septic shock, INCREMENT score ≥8, or bacteremia in immunocompromised/neonatal patients warrant immediate novel agent use 2
- Infection source: Central line-associated bacteremia, endocarditis, mediastinitis, post-neurosurgical infections, or intra-abdominal infections require novel agents empirically 2
- Local epidemiology: Your institution's carbapenem resistance patterns and predominant mechanisms (KPC vs OXA-48 vs MBL) guide selection 3, 1
Pathogen-Specific Empiric Choices
For Suspected CRE (Carbapenem-Resistant Enterobacterales)
Ceftazidime-avibactam is the preferred empiric agent for KPC and OXA-48-like producers, which represent the majority of CRE in most settings 4. If metallo-β-lactamase (MBL) producers are prevalent in your institution, empirically add aztreonam to ceftazidime-avibactam or consider aztreonam-avibactam when available 4. Cefiderocol represents an alternative if susceptibility can be confirmed, though avoid it as first-line empiric therapy given inconsistent mortality data 4.
For Suspected CRAB (Carbapenem-Resistant Acinetobacter baumannii)
Sulbactam-durlobactam is now the preferred treatment, showing superior cure rates (61.9% vs 39.7%) and dramatically reduced nephrotoxicity (13% vs 38%) compared to polymyxin-based regimens 5, 6. The IDSA prioritizes this as first-line therapy for CRAB infections 6, 7. If sulbactam-durlobactam is unavailable, ampicillin-sulbactam can be used for sulbactam-susceptible isolates in pneumonia 1.
For severe CRAB infections when novel agents are unavailable, use combination therapy with two active agents from: polymyxin, aminoglycoside, tigecycline, or sulbactam combinations 1. Avoid polymyxin-meropenem and polymyxin-rifampin combinations—these are strongly recommended against 1.
For Suspected CRPA (Carbapenem-Resistant Pseudomonas aeruginosa)
Novel β-lactam/β-lactamase inhibitors (ceftazidime-avibactam or ceftolozane-tazobactam) are preferred over polymyxins due to significantly lower toxicity (17.9% vs 42.1% adverse events) 5. For severe infections when using older agents, employ combination therapy with two active drugs from polymyxins, aminoglycosides, or fosfomycin 1. Do not use tigecycline for CRPA—it lacks activity 8.
When to De-escalate to Monotherapy
For non-severe or low-risk infections with confirmed susceptibility, monotherapy with an active agent is acceptable based on antibiotic stewardship principles 1. This applies after source control is achieved and clinical improvement is evident.
Critical Adjunctive Measures
Therapeutic drug monitoring (TDM) should be performed when using polymyxins, aminoglycosides, or carbapenems, particularly in critically ill patients, those with renal dysfunction, or infections in difficult-to-penetrate sites (CNS, bloodstream) 3. These narrow therapeutic index drugs require monitoring to prevent both treatment failure and life-threatening toxicity.
For fosfomycin-containing combinations, confirm susceptibility or synergy testing before use, and avoid in patients with hypernatremia, cardiac insufficiency, or renal failure 3.
Common Pitfalls to Avoid
- Do not delay novel agents in septic shock: Mortality benefits are time-dependent; empiric polymyxin use in severe infections shows inferior outcomes 5
- Do not use cefiderocol empirically for CRAB: The ESCMID conditionally recommends against this due to concerning mortality signals in randomized trials 1
- Do not assume all carbapenems are inactive: For CRAB with meropenem MIC ≤8 mg/L, high-dose extended-infusion carbapenem combinations remain viable 1
- Do not use monotherapy for severe infections: Even with novel agents, combination therapy may be warranted for high-risk scenarios, though evidence remains limited 1
Pan-Resistant Organisms
When facing pan-resistant carbapenem-resistant Gram-negatives (including polymyxin resistance), treat with the least resistant antibiotic based on MICs relative to breakpoints, accepting suppressive rather than curative intent 1.